# Medicare negotiated price for ibrutinib (Imbruvica), first cycle

Source: https://onco.cc/terms/medicare-negotiation-2026-cancer-drug/  
OnCo record `medicare-negotiation-2026-cancer-drug` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first ten drugs with a Medicare-negotiated price, in effect from 1 January 2026, included one cancer medicine, ibrutinib (Imbruvica). Its price is set per 30-day supply and rose with inflation from 2027.

## Summary

United States, under the Inflation Reduction Act's Medicare Drug Price Negotiation Program. CMS's data file of 2 November 2026 lists ten selected drugs for initial price applicability year (IPAY) 2026. Ibrutinib (Imbruvica) is the one cancer medicine among them.

The file gives Imbruvica a single maximum fair price of $9,319.00 per 30-day equivalent supply for 1 January to 31 December 2026, and $9,571.07 from 1 January 2027 after the inflation adjustment recorded on 25 November 2025. The file also gives a per-unit price for each package (NDC).

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: IPAY 2026; first cycle of Medicare drug price negotiation; Imbruvica maximum fair price
- Tags: law; us

## Notes

- Figures copied from the 'Single MFP per 30 DES' column of the CMS CSV dated 2 November 2026; the dollar amounts are as CMS wrote them.

## Sources

- CMS: Negotiation Program selected drug list and maximum fair price data file, 2 November 2026 (ZIP): https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip
- CMS: Medicare Drug Price Negotiation Program: https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program

## Connected records

- terms: [Inflation Reduction Act 2022: Medicare drug price negotiation](https://onco.cc/terms/inflation-reduction-act/), [Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib](https://onco.cc/terms/medicare-negotiation-2028-cancer-drugs/), [Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib](https://onco.cc/terms/medicare-negotiation-2027-cancer-drugs/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/medicare-negotiation-2026-cancer-drug.json